Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMG2QP4)

Drug Name	SEP-363856 DMG2QP4
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Schizophrenia	DISSRV2N	6A20	Phase 3	[1]
------------------------------------------------------------------------------------

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Parkinson disease	DISQVHKL	8A00.0	Phase 2	[2]
------------------------------------------------------------------------------------

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Major depressive disorder	DIS4CL3X	6A70.3	Phase 1	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04109950) A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT01994473) Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia. U.S. National Institutes of Health.